Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 68% Improvement Relative Risk Ventilation 31% Combined death/ventilat.. 67% Hospitalization time 7% Ct<30 20% c19early.com/pl Wong et al. Paxlovid for COVID-19 LATE TREATMENT Favors paxlovid Favors control
Wong, 4,943 patient paxlovid late treatment PSM study: 68% lower mortality [p<0.0001], 31% lower ventilation [p=0.41], 67% lower combined mortality/ICU admission [p<0.0001], and 7% shorter hospitalization [p=0.04] https://c19p.org/wong3pl
copied to clipboard
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study
Wong et al., medRxiv, doi:10.1101/2022.05.19.22275291 (Preprint)
20 May 2022    Source   PDF   Share   Tweet
PSM retrospective 40,776 hospitalized patients in Hong Kong, showing lower mortality with paxlovid treatment.
risk of death, 68.0% lower, HR 0.32, p < 0.001, treatment 991, control 3,952, propensity score matching.
risk of mechanical ventilation, 31.0% lower, HR 0.69, p = 0.41, treatment 991, control 3,952, propensity score matching.
combined death/ventilation/ICU, 67.0% lower, HR 0.33, p < 0.001, treatment 991, control 3,952, propensity score matching.
hospitalization time, 6.8% lower, relative time 0.93, p = 0.04, treatment 991, control 3,952, propensity score matching.
Ct<30, 20.0% lower, HR 0.80, p = 0.02, treatment 991, control 3,952, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 5/20/2022, retrospective, China, Asia, preprint, 6 authors, study period 26 February, 2022 - 26 April, 2022.
Contact: carlosho@hku.hk, bcowling@hku.hk.
All Studies   All Outcomes
This PaperPaxlovidAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit